The unprecedented development of vaccines to mitigate the loss of lives due to the pandemic has once more underlined the importance of scientific innovation in our society. Looking ahead, we need to discuss the lessons learned from the COVID-19 pandemic and appreciate the contribution of different players in the field of biomedical infectious diseases innovation. Given the sheer impact of a pandemic on society, we share a responsibility to improve innovation processes in order to maximized speed and output. Both public and private partners have played an important role in
innovation throughout the pandemic. What is the division of responsibility between public and private partners? How has corporate responsibility played a role? What is the business model for preparedness for a next pandemic? How to best invest to improve preparedness? Four keynote speakers will introduce their experiences and view on responsibility towards pandemic preparedness, after which viewpoints will be discussed in a round table session hosted by LUMC and LBSP. Attendance will be through Teams, discussion points may be raised in the chat.
- Prof. dr. Marion Koopmans, Erasmus MC
- Prof. dr. Sarah Gilbert, University of Oxford
- Prof. dr. Matthias Barz, Leiden Academic Center For Drug Research
- Prof. dr. Hanneke Schuitemaker, Janssen Vaccines & Pr evention BV